Lantheus Holdings, Inc. (FRA:0L8)

Germany flag Germany · Delayed Price · Currency is EUR
50.84
+1.02 (2.05%)
At close: Dec 4, 2025
-40.05%
Market Cap 3.61B
Revenue (ttm) 1.30B
Net Income (ttm) 142.91M
Shares Out n/a
EPS (ttm) 2.04
PE Ratio 25.25
Forward PE 11.88
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Average Volume n/a
Open 50.84
Previous Close 49.82
Day's Range 50.84 - 50.84
52-Week Range 41.91 - 100.25
Beta n/a
RSI 60.95
Earnings Date Feb 26, 2026

About Lantheus Holdings

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. The company offers DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked o... [Read more]

Industry In Vitro and In Vivo Diagnostic Substances
Founded 1956
Employees 808
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol 0L8
Full Company Profile

Financial Performance

In 2024, Lantheus Holdings's revenue was $1.53 billion, an increase of 18.32% compared to the previous year's $1.30 billion. Earnings were $312.44 million, a decrease of -4.35%.

Financial numbers in USD Financial Statements

News

There is no news available yet.